Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by UBS Group to Neutral

UBS Group lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a neutral rating in a research note released on Thursday morning, Marketbeat.com reports. UBS Group currently has $738.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $1,130.00.

Other equities research analysts have also recently issued reports about the company. Evercore ISI dropped their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $693.23 on Thursday. Regeneron Pharmaceuticals has a one year low of $666.25 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm’s 50 day moving average price is $744.16 and its 200-day moving average price is $954.41. The firm has a market cap of $76.18 billion, a P/E ratio of 17.15, a P/E/G ratio of 1.60 and a beta of 0.10.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of REGN. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $127,489,000. Icon Wealth Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after purchasing an additional 75,569 shares during the last quarter. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares during the period. Finally, Epoch Investment Partners Inc. grew its stake in Regeneron Pharmaceuticals by 57.7% during the 2nd quarter. Epoch Investment Partners Inc. now owns 163,296 shares of the biopharmaceutical company’s stock worth $171,629,000 after buying an additional 59,745 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.